The data to be presented encompasses five of the company’s novel drug candidates: BCR-ABL tyrosine kinase inhibitor olverembatinib (HQP1351), Bcl-2 inhibitor lisaftoclax (APG-2575), FAK/ALK/ROS1 ...

If approved by the EMA, Vaxchora will be the only single-dose ... and Astellas/Pfizer's Xtandi (enzalutamide). There were also positive opinions from the CHMP for Eli Lilly’s fast-acting ...

Olverembatinib, one of the company’s lead assets, is already approved in China with all of ... the US FDA and 1 Orphan Designation from the EMA of the EU for 4 of the company’s investigational ...

Subsequently, the FDA and EMA advised ... of radium-223 + enzalutamide in combination with a bone protective agent as a new first-line treatment option for mCRPC in patients who have not received a ...

CStone Pharmaceuticals, a biopharmaceutical company dedicated to developing innovative cancer therapies, announced the submission of a Type II variation application to the European Medicines Agency ...

The study, which has an FDA and EMA-approved protocol, will enroll patients in Europe, with the U.S. and Canada expected to follow. The randomized, double-blind, placebo-controlled study aims to ...

As President Donald Trump exits his first 50 days of his second term, his current approval rating hints that Americans are deeply divided as 'the honeymoon' period fades. According to a national ...

More presidential approval rating polls have been released, showing how President Donald Trump is faring in the court of public opinion. Trump had a final approval rating of 34% when he left ...